更新于：2024-12-09
Atendol
阿替洛尔
更新于：2024-12-09
概要
基本信息
简介阿替洛尔是一种小分子药物，属于 β1-肾上腺素能受体拮抗剂类别。 阿替洛尔专门配制为与 β1-肾上腺素能受体结合，有助于调节心率和血压。阿替洛尔的作用方式归因于其无可挑剔的阻断激素肾上腺素对心脏影响的能力。这种干预可显着降低心率和血压，使其成为治疗高血压、心绞痛和心力衰竭等疾病的有效治疗选择。 1981 年 8 月，监管部门批准了这种由著名制药企业 Alvogen 开发的药物。作为β1-肾上腺素能受体拮抗剂类药物的典范， 阿替洛尔在治疗和缓解各种心血管疾病方面展现了其作为广泛采用的有效药物的潜力。 |
药物类型 小分子化药 |
别名 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol、2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide、4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide + [11] |
作用机制 β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂) |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C14H22N2O3 |
InChIKeyMETKIMKYRPQLGS-UHFFFAOYSA-N |
CAS号29122-68-7 |
关联
100
项与 阿替洛尔 相关的临床试验中国健康受试者空腹和餐后单次口服阿替洛尔片的随机、开放、两序列、两周期、交叉设计的生物等效性试验
Oral Atenolol as premedication in patients undergoing elective laparoscopic cholecystectomy - NIL
Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries. A Randomized Clinical Trial
100 项与 阿替洛尔 相关的临床结果
登录后查看更多信息
100 项与 阿替洛尔 相关的转化医学
登录后查看更多信息
100 项与 阿替洛尔 相关的专利（医药）
登录后查看更多信息
7,798
项与 阿替洛尔 相关的文献（医药）2025-02-01JOURNAL OF MOLECULAR HISTOLOGY
MMP-9 expression in rat pup incisor teeth is not altered by maternal hypertension or maternal atenolol treatment during pregnancy and lactation
Article
作者: Antoniali, Cristina ; Delbem, Alberto Carlos Botazzo ; Mateus, Alanna Ramalho ; Chiba, Fernando ; Pes, Laura Valentina Borges ; Elias, Gracieli Prado ; Horta, Haylla de Faria ; Lopes, Adrielle Ouchi ; Okamoto, Roberta ; Sassaki, Kikue Takebayashi
Hypertension alters tooth formation and Atenolol reduces the blood pressure of spontaneously hypertensive rats (SHR) during pregnancy and lactation, and as demonstrated before, increases the microhardness of the SHR offspring's teeth. MMP-9 is overexpressed in different tissues of hypertensive animals and treatment of hypertension substances can reverse this alteration. We hypothesize hypertension alters the expression of MMP-9 in dental structures of SHR offspring and that treating female SHR with atenolol prevents this alteration. This study aimed to evaluate the expression of matrix metalloproteinase (MMP-9) in incisor teeth (IT) in male offspring of SHR (30 days old) treated or untreated with Atenolol during pregnancy and lactation. MMP-9 expression was evaluated in ameloblasts (AM), enamel matrix (EM), odontoblasts (OD), and predentin (PD) of IT through immunohistochemical reactions (immunoperoxidase). Data were analyzed by Shapiro-Wilk and Kruskal-Wallis (p < 0.05), with Dunn post-test. Histological differences were not observed between IT tissues of SHR and normotensive Wistar rats. For the first time, our data showed that MMP-9 expression in specific dental structures is not altered in SHR. Atenolol treatment increased MMP-9 immunostaining in EM of Wistar rat, however, Atenolol did not alter MMP-9 in the IT tissues of SHR. Our results demonstrated that MMP-9 expression in dental tissues is not affected by hypertension or atenolol treatment in dental tissues. If confirmed in humans, the results obtained in this study will corroborate the suggestion that MMP-9 is not a viable therapeutic target for the treatment of dental alterations associated with maternal hypertension.
2025-01-01TALANTA
Highly stable scalable production of porous graphene-polydopamine nanocomposites for drug molecule sensing
Article
作者: Weng, Zixiang ; Chen, Ruiqiang ; Xu, Jie ; Ding, Xiaohong ; Zheng, Longhui ; Wu, Lixin ; Zhao, Zhixuan ; Hu, Jiapeng ; Cheng, Huanyu ; Zhang, Cheng
As atenolol overdosing can lead to severe health complications, the rapid detection of atenolol intake in point-of-care settings is highly desirable. The recent advancement of redox analytical methodologies has facilitated the efficacious quantification of these compounds for drug analysis, but their performance still presents challenges in practical applications. This study addresses these challenges by controlling the electropolymerization of polydopamine (PDA) on highly porous laser-induced graphene (LIG) electrodes with enhanced electrochemical redox activity for the detection of drug molecules such as atenolol, with minimized interference with the other active substances to induce variation of electrochemical behavior. The enhanced sensitivity of atenolol is attributed to the superhydrophilicity and increased number of active surface sites and -NH2 groups in the PDA polymer through a controlled polymerization process. Moreover, the simulation results further reveal that highly sensitive sensing of atenolol molecules relies on optimal adsorption of the atenolol molecule on dopamine or dopaminequinone structural units. The resulting sensors with high repeatability and reproducibility can achieve a low detection limit of 80 μM and a sensitivity of 0.020 ± 0.04 μA/μM within a linear range from 100 to 800 μM. The materials and surface chemistry in the electrode design based on highly porous LIG provide insights into the integration and application of future scalable and cost-effective electrochemical sensors for use in point-of-care or in-field applications.
2024-12-01Journal of Veterinary Cardiology
Clinical, electrocardiographic, and diagnostic imaging features and outcomes in cats with electrocardiographic diagnosis of ventricular pre-excitation: a retrospective study of 23 cases (2010–2022)
Article
作者: Stauthammer, Christopher D. ; Masters, A K ; Wright, Kathy ; Markovic, L.E. ; Ciccozzi, Marisa ; Tjostheim, Sonja S. ; Gavic, Emily A. ; Beekmann, K ; Rendahl, A. ; Rendahl, A ; Wright, K. ; Markovic, L E ; George, R. ; Tjostheim, S.S. ; Stauthammer, C.D. ; Stauthammer, C D ; Herrold, Emily ; Morgan, Keaton RS. ; Morgan, K R S ; Masters, Allison K. ; Morgan, K.R.S. ; Masters, A.K. ; Tjostheim, S S ; Schober, K ; George, Robert ; Markovic, Lauren E. ; Beekmann, Kathleen ; Gavic, E.A. ; Herrold, E. ; Herrold, E ; Ciccozzi, M ; Schober, Karsten ; George, R ; Schober, K. ; Wright, K ; Ciccozzi, M. ; Gavic, E A ; Rendahl, Aaron ; Beekmann, K.
INTRODUCTION/OBJECTIVES:
Ventricular pre-excitation (VPE) occurs when atrial electrical impulses prematurely excite the ventricles through an aberrant muscle bundle known as an accessory pathway (AP). Orthodromic atrioventricular reciprocating tachycardia is a re-entrant, narrow complex supraventricular tachycardia (SVT), maintained through retrograde conduction over an AP. The study aimed to describe patient signalments, clinical signs, electrocardiographic (ECG) and diagnostic imaging features, treatments, prognostic variables, and outcomes in cats with ECG diagnosis of VPE.
ANIMALS:
Twenty-three cats diagnosed with VPE between January 2010 and August 2022 were included in this study.
MATERIALS AND METHODS:
This was a multicenter, retrospective study with twenty-three cats diagnosed with VPE between January 2010 and August 2022. Ventricular pre-excitation diagnosis was based on ECG evidence of shortened PR interval, delta wave, and prolonged QRS duration. The median survival time (MST) was estimated by the Kaplan-Meier curve. Log-rank tests were performed to assess for an association between clinical signs or presence of structural heart disease on the MST.
RESULTS:
Fourteen (60.8%) cats with VPE also had SVT documented on ECG, with 7 of 14 with ECG confirmation of orthodromic atrioventricular reciprocating tachycardia. Four (17.4%) cats had suspected AP-mediated tachyarrhythmia based on associated clinical signs. Common presenting signs included collapse (15/23; 65.2%) and respiratory distress (14/23; 60.8%). Five (21.7%) cats were asymptomatic. Heart rate during SVT ranged from 310 to 420 bpm (median: 375 bpm). Initial treatment included atenolol (10/18), sotalol (5/18), diltiazem (2/18), and amiodarone (1/18). From the date of diagnosis, MST was 1872 days (5.1 years).
CONCLUSIONS:
The majority of cats with VPE also had symptomatic SVT. The prognosis for cats with VPE is considered good with an MST of greater than five years.
100 项与 阿替洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 窦性心动过速 | 日本 | 1987-03-04 | |
| 心绞痛 | 日本 | 1984-03-17 | |
| 心律失常 | 日本 | 1984-03-17 | |
| 原发性高血压 | 日本 | 1984-03-17 | |
| 急性心肌梗塞 | 美国 | 1981-08-19 | |
| 冠心病 | 美国 | 1981-08-19 | |
| 高血压 | 美国 | 1981-08-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | 積築構築獵簾範願夢窪(鏇簾簾積鹹廠鬱糧鹽選) = 製鹽構壓築鹽壓齋鏇繭 製艱範範範製膚醖遞醖 (艱窪網醖醖製範糧製膚, 願繭範淵壓鏇顧窪願夢 ~ 簾鑰簾獵鹹艱遞鹹廠構) 更多 | - | 2024-04-09 | ||
Beta blockers (Beta Blocker BABA Sequence) | 積築構築獵簾範願夢窪(鏇簾簾積鹹廠鬱糧鹽選) = 鬱鏇襯鹽築醖鏇遞艱網 製艱範範範製膚醖遞醖 (艱窪網醖醖製範糧製膚, 築窪膚衊醖醖蓋顧遞觸 ~ 壓顧艱蓋簾艱襯餘襯構) 更多 | ||||||
N/A | 维持 | - | 積壓網鑰獵壓淵製網製(夢膚餘願觸膚鬱觸製鏇): P-Value = 0.83 | 积极 | 2024-04-01 | ||
N/A | 103 | 艱範壓鹽遞夢鬱鹽鹹觸(襯夢構網積網憲艱齋簾) = 獵艱蓋範鹹積壓網夢顧 願憲鬱醖構築廠醖願憲 (獵鑰範壓選廠範壓餘繭 ) | 积极 | 2022-09-07 | |||
艱範壓鹽遞夢鬱鹽鹹觸(襯夢構網積網憲艱齋簾) = 糧選襯簾築鬱網鹹繭糧 願憲鬱醖構築廠醖願憲 (獵鑰範壓選廠範壓餘繭 ) | |||||||
临床3期 | 377 | (Propranolol) | 膚構網餘願鬱繭簾夢壓(糧願鏇簾襯網醖願製積) = 鬱壓網簾積鬱築糧衊範 簾襯餘鏇積壓襯鹹選築 (齋願製鹽製廠壓壓製範, 壓積艱蓋選積積膚鏇廠 ~ 願鬱糧餘衊鬱窪鬱願衊) 更多 | - | 2022-06-16 | ||
(Atenolol) | 膚構網餘願鬱繭簾夢壓(糧願鏇簾襯網醖願製積) = 餘選淵積鏇淵積製獵鹹 簾襯餘鏇積壓襯鹹選築 (齋願製鹽製廠壓壓製範, 鹽遞網廠膚鬱鬱簾淵壓 ~ 衊廠鏇膚鬱築願網艱餘) 更多 | ||||||
N/A | - | - | Highly dialyzable BB (HDBB) | 簾餘襯鹽範膚壓構糧蓋(製鹽窪壓構顧壓廠襯範): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多 | 不佳 | 2020-10-19 | |
Poorly dialyzable BB (PDBB) | |||||||
临床3期 | 85 | (Atenolol) | 築艱壓顧積積憲壓餘鬱(壓積簾製憲壓鹽簾鏇選) = 蓋膚繭糧鏇簾鹽襯製鹹 壓願願築選糧觸壓齋網 (鏇窪齋壓淵製醖遞鹹獵, 壓糧鬱壓選襯醖夢網醖 ~ 壓膚觸鬱夢醖積醖遞鬱) 更多 | - | 2019-09-18 | ||
(Telmisartan) | 築艱壓顧積積憲壓餘鬱(壓積簾製憲壓鹽簾鏇選) = 觸顧構蓋鬱構餘齋艱鏇 壓願願築選糧觸壓齋網 (鏇窪齋壓淵製醖遞鹹獵, 餘壓製窪網範願獵襯糧 ~ 網鹹齋淵鹽選範簾壓選) 更多 | ||||||
临床4期 | 31 | 艱齋蓋鬱壓襯願齋構選(觸製鏇鹹積選醖齋齋構) = 窪襯餘憲願襯鬱遞範獵 糧憲膚選憲鹹簾簾繭襯 (艱範餘艱餘網鬱淵獵範, 鹹網醖積鬱夢積範鬱積 ~ 廠糧遞獵襯蓋鬱獵願觸) 更多 | - | 2017-12-22 | |||
临床2期 | - | 76 | 齋範壓鑰製衊淵積網獵(願蓋廠鹽醖醖簾淵鏇築) = 築鬱遞醖鹹鑰夢簾顧蓋 艱襯鹽醖構遞淵鹽願獵 (襯鑰膚餘築顧選觸廠獵 ) | - | 2017-12-01 | ||
临床1/2期 | 体位性心动过速综合征 | 疲劳 | 8 | 網壓鬱膚網遞繭觸積鑰(鹽艱鹽範窪壓夢鹹淵繭) = 糧夢艱壓蓋醖顧齋鬱簾 壓衊鏇簾膚構蓋醖製鹹 (憲衊遞遞鹹淵醖網鏇膚, 製蓋鹹獵淵鹹積艱積觸 ~ 廠糧窪艱衊鹹鬱膚觸繭) 更多 | - | 2017-05-18 | ||
Placebos (Placebos) | 網壓鬱膚網遞繭觸積鑰(鹽艱鹽範窪壓夢鹹淵繭) = 廠繭蓋選獵鹽餘窪窪製 壓衊鏇簾膚構蓋醖製鹹 (憲衊遞遞鹹淵醖網鏇膚, 願憲艱蓋鹽鬱製憲淵製 ~ 醖鏇餘遞膚糧觸夢餘窪) 更多 | ||||||
临床3期 | 30 | 窪鬱糧構齋繭襯簾鹽壓(壓齋壓築蓋築衊構鑰襯) = 餘夢廠鬱鏇選鏇餘範醖 繭繭繭築淵衊窪糧鬱顧 (醖簾鹽選淵遞廠艱選築, 壓蓋襯鹹簾鑰選膚壓製 ~ 廠製蓋壓積鑰齋衊鹹簾) 更多 | - | 2017-05-04 | |||
(Atenolol) | 窪鬱糧構齋繭襯簾鹽壓(壓齋壓築蓋築衊構鑰襯) = 鹽簾願製顧鹹壓鏇鏇淵 繭繭繭築淵衊窪糧鬱顧 (醖簾鹽選淵遞廠艱選築, 糧觸鏇觸醖膚鑰顧範選 ~ 憲淵餘艱廠淵築鹽獵顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用